Breakeven Date Change • May 20
Forecast to breakeven in 2028 The analyst covering OptiCept Technologies expects the company to break even for the first time. New forecast suggests losses will reduce by 85% per year to 2027. The company is expected to make a profit of kr15.0m in 2028. Average annual earnings growth of 105% is required to achieve expected profit on schedule. Board Change • May 20
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. Chairman of the Board Ulf Hagman is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Dec 19
Opticept Technologies AB (Publ) Appoints Mikael Carleson and Jörgen Durban as Board Members OptiCept Technologies AB (publ) at its EGM held on December 18, 2025 appointed Mikael Carleson and Jörgen Durban were elected as new Board members. Duyuru • Oct 22
OptiCept Technologies AB (publ), Annual General Meeting, May 21, 2026 OptiCept Technologies AB (publ), Annual General Meeting, May 21, 2026. Duyuru • Nov 29
OptiCept Technologies AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 80.463125 million. OptiCept Technologies AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 80.463125 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 16,092,625
Price\Range: SEK 5
Transaction Features: Rights Offering Duyuru • Nov 27
OptiCept Technologies AB (publ) Expands Project with Dole in Thailand OptiCept has successfully completed its project with Dole in Thailand, which was announced in the spring of 2024. Following positive results, Dole has decided to extend and expand the collaboration to further explore the potential of OptiCept's technology platforms. The focus is now on optimizing the drying process for pineapples. During the initial 14-day pilot period, OptiCept achieved the project goals. The treatment resulted in improved texture in pineapple products, making them more appealing to new markets with high-quality standards. At the same time, an evaluation of the drying process showed significantly increased efficiency through reduced drying times. As a result, Dole wants to conduct further tests to fully map the commercial benefits of PEF (Pulsed Electric Field) technology in the pineapple drying process. The project is therefore entering a commercial phase. Thailand is a globally significant producer of pineapples, with an annual production of approximately 1.2 million tons, placing the country among the top five producers worldwide. Asia is also the world's largest region in terms of both production and consumption of pineapples, making the Thai market a strategic priority for OptiCept. Buy Or Sell Opportunity • Nov 11
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 27% to €0.41. The fair value is estimated to be €0.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 749% in 2 years. Earnings are forecast to grow by 93% in the next 2 years. Breakeven Date Change • Oct 21
Forecast to breakeven in 2026 The 2 analysts covering OptiCept Technologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 51% per year to 2025. The company is expected to make a profit of kr1.85m in 2026. Average annual earnings growth of 87% is required to achieve expected profit on schedule. Reported Earnings • Oct 19
Third quarter 2024 earnings released: kr0.28 loss per share (vs kr0.67 loss in 3Q 2023) Third quarter 2024 results: kr0.28 loss per share (improved from kr0.67 loss in 3Q 2023). Net loss: kr13.1m (loss narrowed 37% from 3Q 2023). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Machinery industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. New Risk • Oct 18
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: kr67m Forecast net loss in 3 years: kr622k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr67m). Currently unprofitable and not forecast to become profitable over next 3 years (kr622k net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (kr15m revenue, or US$1.4m). Market cap is less than US$100m (€34.0m market cap, or US$36.9m). Duyuru • Oct 11
OptiCept Technologies AB (publ), Annual General Meeting, May 22, 2025 OptiCept Technologies AB (publ), Annual General Meeting, May 22, 2025. New Risk • Oct 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr67m). Revenue is less than US$5m (kr15m revenue, or US$1.4m). Market cap is less than US$100m (€27.6m market cap, or US$30.3m). Duyuru • Oct 03
Opticept Technologies AB (publ) Announces Chief Financial Officer Changes OptiCept Technologies AB (publ) announced that OptiCept's Chief Financial Officer, Despina Georgiadou Hedin, has decided to step down from her role. Henrik Nettersand will be the new CFO. Despina Georgiadou Hedin, who has been CFO at OptiCept Technologies since 2023, will leave her position no later than April 2, 2025. Henrik Nettersand, currently CFO at S:t Eriks AB, will succeed her. Henrik Nettersand most recently served as CFO at S:t Eriks AB and will assume his new role no later than April 2, 2025. Previously, he was CFO at Besikta Bilprovning for five years and held several leadership roles during his eleven years at John Bean Technologies AB, including as Head of Finance. He began his career as an auditor at KPMG and holds a Master of Science in Economics and Business Administration from Lund University, with a specialization in finance. Henrik has many years of experience in financial leadership roles, both at the company and group levels, and has extensive global experience. His long experience working with multinational companies in growth, both inside and outside Sweden, and with companies delivering complex food technology globally, has given him the expertise and business focus the company need in its global expansion. New Risk • Sep 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr67m). Revenue is less than US$5m (kr15m revenue, or US$1.4m). Market cap is less than US$100m (€23.2m market cap, or US$25.8m). Reported Earnings • Aug 30
Second quarter 2024 earnings released: kr0.23 loss per share (vs kr0.57 loss in 2Q 2023) Second quarter 2024 results: kr0.23 loss per share (improved from kr0.57 loss in 2Q 2023). Net loss: kr10.3m (loss narrowed 39% from 2Q 2023). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Machinery industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 17
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 153% to €0.59. The fair value is estimated to be €0.48, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has declined by 13%. Revenue is forecast to grow by 1,205% in 2 years. Earnings are forecast to grow by 81% in the next 2 years. Duyuru • Jul 02
OptiCept Technologies AB Submits Patent Application and Strengthens Its IP-Portfolio for Vacuum Impregnation Focused on Cuttings OptiCept Technologies AB announced that the company has submitted a patent application to the Swedish Patent and Registration Office (PRV). The patent application includes strengthened and expanded patent protection for the company's vacuum impregnation technology, OptiBoost. OptiCept brings the vacuum infusion platform to the next level by specifying the successful treatment conditions for its plant technology platform, OptiBoost. The patent application encompasses the detailed method of treating the plant material such as cuttings leading to improved rooting. Successes with tests on cuttings have prompted the submission of the patent application. The company learns and develops with every new test. The method that OptiCept uses is mastered, and the knowledge of how to control and implement it is becoming stronger and stronger with new activities and a growing portfolio of tested species.The patent application expounds the exact conditions for applying the vacuum infusion process to achieve the most optimal treatment for plants. The treatment must be mild and well-controlled to minimize the stress applied to the plant tissue, which is ensured by the innovative way of designing the vacuum curve. The patent also describes the correct treatment criteria by controlling the percentage of air removed from the tissue and percentage of liquid incorporated into the tissue by specifying the surface impregnation parameters. Buy Or Sell Opportunity • Jul 01
Now 3.4% overvalued after recent price rise Over the last 90 days, the stock has risen 83% to €0.46. The fair value is estimated to be €0.44, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has declined by 13%. Revenue is forecast to grow by 1,205% in 2 years. Earnings are forecast to grow by 81% in the next 2 years. Buy Or Sell Opportunity • Jun 25
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 95% to €0.50. The fair value is estimated to be €0.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has declined by 13%. Revenue is forecast to grow by 1,205% in 2 years. Earnings are forecast to grow by 81% in the next 2 years. Breakeven Date Change • Jun 05
Forecast to breakeven in 2026 The 2 analysts covering OptiCept Technologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 60% per year to 2025. The company is expected to make a profit of kr6.00m in 2026. Average annual earnings growth of 82% is required to achieve expected profit on schedule. Reported Earnings • Jun 04
First quarter 2024 earnings released: kr0.35 loss per share (vs kr0.71 loss in 1Q 2023) First quarter 2024 results: kr0.35 loss per share (improved from kr0.71 loss in 1Q 2023). Net loss: kr14.7m (loss narrowed 30% from 1Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Machinery industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. Board Change • May 30
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Anders Hattmark was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Duyuru • Apr 12
OptiCept Technologies AB Files Patent Application for Combined PEF and VI Treatment of Fruit and Vegetable Products OptiCept Technologies AB announced that the company has submitted a new patent application to the Swedish Intellectual Property Office (PRV). The patent application includes a new application area for the company's technologyplatforms CEPT (Controlled Environment PEF treatment) and VI (Vacuum infusion) in fruit and vegetable processing. Success with tests on pineapple chunks has prompted the filing of the patent application. OptiCept has developed a new application area for the company's technology platforms. The patent application includes a Pulsed Electric Field (PEF) step followed by a vacuum injection step, or the steps separately for softening fruit or vegetable products (pieces of fruit or vegetables), where the fruit or vegetable products are impregnated with fruit or vegetable juice to improve product color and texture. This new technology can naturally improve the organoleptic properties of products to be even more appreciated by consumers due to improved texture, consistency, and color. It also creates the conditions to produce completely new products. Success with tests on pineapple chunks has prompted the filing of the patent application. Reported Earnings • Feb 28
Full year 2023 earnings released: kr2.48 loss per share (vs kr5.03 loss in FY 2022) Full year 2023 results: kr2.48 loss per share (improved from kr5.03 loss in FY 2022). Net loss: kr80.4m (loss narrowed 20% from FY 2022). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Machinery industry in Germany. Duyuru • Feb 27
OptiCept Technologies AB (publ), Annual General Meeting, May 24, 2024 OptiCept Technologies AB (publ), Annual General Meeting, May 24, 2024. Duyuru • Dec 22
OptiCept Technologies AB (publ) Receives First Partial Results from the Pilot Project to Improve the Staining of Cuttings in China OptiCept Technologies AB (publ) announced that it has received the first partial results from the pilot project to improve the rooting of cuttings in China, which initially focuses on Acacia. The root of Acacia cuttings improved by 12-33% depending on the type of Acacia treated. In May 2023, OptiCept Technologies entered an agreement with Guangxi Shichen Group ("GSG"), in collaboration with the Chinese state research institute Guangxi Academy of Forestry, to evaluate the OptiBoost technology on several different types of cuttings to improve its rooting. Acacia cuttings treated with the patented vacuum impregnation technology show an average improved rooting of 12-33% after 45 days, with the final assessment made after 90 days. Results from the evaluation of Camelia will be available in 2024 when tests for Eucalyptus also will be carried out. Acacia is a large genus with many species. Cultivation of Acacia is particularly common in China, Southeast Asia, South America, Africa, and in Australia, where Acacia forest is the second most common forest type after Eucalyptus forest. Acacia is one of the most cultivated trees in the southern hemisphere and is a fast-growing species that can grow in harsh conditions that other species cannot, which can quickly generate yields. Reported Earnings • Nov 30
Third quarter 2023 earnings released: kr0.67 loss per share (vs kr1.09 loss in 3Q 2022) Third quarter 2023 results: kr0.67 loss per share (improved from kr1.09 loss in 3Q 2022). Net loss: kr20.7m (loss narrowed 4.4% from 3Q 2022). Revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Machinery industry in Germany. New Risk • Oct 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.39m (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m (kr10m revenue, or US$925k). Market cap is less than US$10m (€9.39m market cap, or US$9.95m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr104m). Currently unprofitable and not forecast to become profitable over next 2 years (kr14m net loss in 2 years). Duyuru • Oct 22
OptiCept Technologies AB (publ) Announces CFO Changes OptiCept Technologies AB (publ) recruited Déspina Georgiadou Hedin as the company's new CFO. Déspina most recently comes from Ascelia Pharma AB (publ), where she held the position of CFO. She will take up her position no later than 1 November 2023. Déspina Georgiadou Hedin now replaces Tomas Andersson, who acted as interim CFO since April 2023 while a permanent recruitment was carried out. She has extensive experience in leading positions in finance and the role of CFO for both listed and unlisted companies. Most recently, she was the CFO at Ascelia Pharma AB and before that, she was, among other things, CFO and HR manager at Bioglan AB, as well as Chief Accountant and Senior Financial Specialist at Sol Voltaics AB. Déspina has a bachelor's degree in economics from Linnaeus University, Växjö/Kalmar. Reported Earnings • Aug 30
Second quarter 2023 earnings released: kr0.57 loss per share (vs kr1.10 loss in 2Q 2022) Second quarter 2023 results: kr0.57 loss per share (improved from kr1.10 loss in 2Q 2022). Net loss: kr17.1m (loss narrowed 22% from 2Q 2022). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Machinery industry in Germany. Duyuru • Feb 07
OptiCept Technologies AB (publ), Annual General Meeting, Mar 08, 2023 OptiCept Technologies AB (publ), Annual General Meeting, Mar 08, 2023. Breakeven Date Change • Nov 16
Forecast breakeven date pushed back to 2024 The analyst covering OptiCept Technologies previously expected the company to break even in 2022. New forecast suggests losses will reduce by 35% per year to 2023. The company is expected to make a profit of kr2.00m in 2024. Average annual earnings growth of 87% is required to achieve expected profit on schedule. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Director Elisabeth Yllfors was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Breakeven Date Change • Nov 08
Forecast breakeven date pushed back to 2024 The analyst covering OptiCept Technologies previously expected the company to break even in 2022. New forecast suggests losses will reduce by 35% per year to 2023. The company is expected to make a profit of kr2.00m in 2024. Average annual earnings growth of 87% is required to achieve expected profit on schedule. Duyuru • Oct 01
Thomas Lundqvist acquired additional minority stakes in OptiCept Technologies AB (publ) (OM:OPTI). Thomas Lundqvist acquired additional minority stakes in OptiCept Technologies AB (publ) (OM:OPTI) on September 29, 2022. Thomas Lundqvist ill acquire 5300 shares at a price of SEK 28.28.
Thomas Lundqvist completed the acquisition of additional minority stakes in OptiCept Technologies AB (publ) (OM:OPTI) on September 29, 2022. Duyuru • May 17
Opticept Technologies AB (publ) Announces CEO Changes OptiCept Technologies' CEO Johan Möllerström has chosen to resign as CEO from the Annual General Meeting on May 25, 2022. The new CEO will be Thomas Lundqvist, who is currently part of the management team as Head of Sales. Johan Möllerström has been CEO of ArcAroma and now OptiCept for 5.5 years and over the years has changed the companies' focus from biogas to food, from freezing processes to cut flowers, and from innovation to commercial success. Reported Earnings • May 09
First quarter 2022 earnings released: kr0.74 loss per share (vs kr0.47 loss in 1Q 2021) First quarter 2022 results: kr0.74 loss per share (down from kr0.47 loss in 1Q 2021). Net loss: kr14.8m (loss widened 162% from 1Q 2021). Over the next year, revenue is forecast to grow 4,589%, compared to a 8.9% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (5 non-independent directors). Director Elisabeth Yllfors was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 10
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr2.61 loss per share (down from kr1.23 loss in FY 2020). Net loss: kr42.5m (loss widened 199% from FY 2020). Revenue missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 2,568%, compared to a 10% growth forecast for the industry in Germany. Breakeven Date Change • Sep 23
Forecast to breakeven in 2021 The analyst covering OptiCept Technologies expects the company to break even for the first time. New forecast suggests the company will make a profit of kr40.0m in 2021. Earnings growth of 89% is required to achieve expected profit on schedule. Reported Earnings • Feb 18
Full year 2020 earnings released: kr1.03 loss per share (vs kr0.81 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr3.33m (down 40% from FY 2019). Net loss: kr11.9m (loss widened 43% from FY 2019). Duyuru • Feb 18
OptiFreeze AB (publ) (NGM:OPTI) agreed to acquire ArcAroma AB (publ) (OM:AAA). OptiFreeze AB (publ) (NGM:OPTI) agreed to acquire ArcAroma AB (publ) (OM:AAA) on February 16, 2021. The transaction is subject to shareholders approval of ArcAroma AB (publ). The transaction is approved by the Board of ArcAroma AB (publ).